Phase 2 N=171 Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305
Atrial Fibrillation
Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,504 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Atrial Fibrillation
Primary: Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism…
Phase 3 N=112 Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Atrial Fibrillation · Cardioversion · Cerebrovascular Stroke
Primary: Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli — 9; 11 Participants
N/A N=261 Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial
Atrial Fibrillation
Primary: Number of Participants With Successful Cardioversion of Atrial Fibrillation to Sinus Rhythm — 114; 111 Participants
N/A N=546 Clinical Trial Comparing Devices Used for Cardioversion of Atrial Fibrillation
Atrial Fibrillation
Primary: The Number of Participants in Normal Sinus Rhythm (NSR) by ECG After the First DCCV Shock — 223; 233 Participants — p=0.565
N/A N=4,658 International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)
Atrial Fibrillation
Primary: Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) — 1.3; 1.6; 1.4; 2.3 Percentage of Participants
N/A N=102 Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus
Atrial Fibrillation
Primary: Time to Imaging — 28.1; 7.1 hours
Phase 2 N=241 Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Persistent Atrial Fibrillation
Primary: Time From Randomization to First Documented AF Recurrence. — 51.0; NA; 117.0; 58.0 Days
Phase 2 N=66 A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
Atrial Fibrillation
Primary: Percentage of Participants Who Converted From Atrial Fibrillation (AF) Within 90 Minutes From Start of Infusion and Subsequently Had no AF Recurrence Within 1 Minute of…
Phase 4 N=73 Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
Atrial Fibrillation · Atrial Flutter
Primary: Time From Initiation of Sedation to Full Recovery — 7.6; 5.5 minutes
N/A N=20 Investigation of Therapeutic Ablation Versus Cardioversion for AF
Persistent Atrial Fibrillation · Cardiac Arrhythmia
Primary: Recurrence of Persistent AF (of AF Episode Lasting > 7 Days). — 3; 6 Participants
Phase 3 N=2,199 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
Atrial Fibrillation
Primary: Percentage of Participants With Composite Endpoint of Stroke, Systemic Embolic Stroke (SEE), Myocardial Infarction (MI) and Cardiovascular (CV) Mortality From…
N/A N=610 REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
Heart Failure
Primary: Percentage of Patients Worsened for Clinical Composite Response — 21.5; 16 Percentage of participants worsened — p=0.10
Phase 4 N=1,500 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Atrial Fibrillation
Primary: Number of Participants With Acute Stroke Event — 0; 6 participants — p=0.0151
Phase 2 N=134 Efficacy and Safety Study of F373280
Atrial Fibrillation
Primary: Time to First Atrial Fibrillation (AF) Recurrence or Atrial Flutter Emergence Defined by the Time to First Episode of AF or Atrial Flutter Lasting for at Least 10…
Phase 2 N=19 Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia
Ventricular Tachycardia · Cardiomyopathy · Premature Ventricular Contractions
Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events
Phase 2 N=186 REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: The Incidence of Early Onset Primary Adverse Events — 5.5 percentage of participants
Phase 2 N=104 Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Symptomatic Atrial Fibrillation · Atrial Flutter
Primary: Conversion to Sinus Rhythm — 4; 4; 11; 13 participants
N/A N=234 CARTO® 3 System and Real Time Intracardiac Ultrasound
Atrial Fibrillation · Paroxysmal AF
Primary: Total Fluoroscopy Time — 28.3 minutes
N/A N=342 Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation
Other Intraoperative Cardiac Functional Disturbances During Cardiac Surgery
Primary: Participants Experiencing Ventricular Fibrillation Requiring Defibrillation During the 60 Minute Period Following Myocardial Reperfusion — 66; 60; 70 Participants…
N/A N=48 Acute Subcutaneous Defibrillation
Ventricular Arrhythmias
Primary: Subjects Will Demonstrate a Successful Defibrillation Outcome if They Have 2 Successful Defibrillation Shocks With the Research System. — 85.7 percentage of success
N/A N=13 ASSURE WCD Clinical Evaluation - Conversion Efficacy Study
Death, Sudden, Cardiac
Primary: Cumulative First and Second Shock VT/VF Conversion Rate — 100; 100 percentage
Phase 3 N=221 Biphasic Defibrillation Study: Trial to Compare Fixed Versus Escalating Energy
Cardiac Arrest
Primary: Successful Conversion to an Organized Heart Rhythm — 28; 39 Participants
N/A N=272 A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)
Atrial Fibrillation
Primary: Number of Participants With Primary Adverse Events (PAEs) — 0; 0; 0 Participants
N/A N=100 Comparison of VF Induction Techniques During Medtronic ICD Implant (VF) (ICD)
Cardiomyopathy
Primary: Sustained Ventricular Fibrillation — 38; 35 participants
N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
N/A N=3,889 Improve Sudden Cardiac Arrest Study
Sudden Cardiac Arrest · Ventricular Arrythmia
Primary: Time to the First Occurrence of a Ventricular Arrhythmia — 32.5; 18.3 Estimated 24-Month VT-VF Pct of Patients
Phase 3 N=523 Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Postoperative Atrial Fibrillation
Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76
N/A N=16 Using Electrical Nerve Stimulation to Control Atrial Fibrillation
Atrial Fibrillation
Primary: Change in AF Burden — -0.4; -2.4 percentage of time in AF
Phase 2 N=349 Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
Fibrillation, Atrial
Primary: Number of Participants With at Least One Event of Cerebral Neurologic Event, Systemic Thromboembolism, Death From Any Cause, and/or Major Bleeding Until the End of…